Table 3.
Predictors of disease-free survival in ESCC patients with Non-pCR to neoadjuvant chemoradiotherapy.
| Clinicopathologic Parameters | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Age (y) | ||||
| ≤55 VS >55 | 0.945(0.570–1.566) | 0.826 | ||
| Sex | ||||
| Female VS Male | 1.611(0.584–4.441) | 0.357 | ||
| Smoking | ||||
| No VS Yes | 1.000(0.605–1.653) | 1.000 | ||
| Prognostic nutritional index | ||||
| <49 VS ≥49 | 1.179(0.716–1.940) | 0.518 | ||
| Tumor location | ||||
| Upper VS Middle | 1.172(0.633–2.170) | 0.613 | ||
| Upper VS Distal | 1.769(0.801–3.904) | 0.158 | ||
| Primary tumor length | ||||
| <7 cm VS ≥7cm | 1.087(0.660–1.790) | 0.743 | ||
| Clinical T stage | ||||
| T2 VS T3 | 0.427(0.057–3.187) | 0.427 | ||
| T2 VS T4 | 0.527(0.070–3.975) | 0.534 | ||
| Clinical N stage | ||||
| N0 VS N+ | 1.440(0.709–2.922) | 0.313 | ||
| Clinical TNM stage | ||||
| II VS III | 1.074(0.450–2.564) | 0.872 | ||
| II VS IV | 1.237(0.503–3.039) | 0.643 | ||
| yp T stage | ||||
| T0–2 VS T3–4 | 1.516(0.908–2.531) | 0.112 | ||
| yp T stage | ||||
| N0 VS N+ | 1.230(0.742–2.041) | 0.422 | ||
| yp TNM stage | ||||
| I/II VS III/VI | 1.607(0.946–2.727) | 0.079 | 1.328(0.803–2.197) | 2.269 |
| Radiation dose (Gy) | ||||
| <40 VS ≥40 | 0.834(0.5489–1.421) | 0.504 | ||
| Radiotherapy modality | ||||
| 2DTR VS 3DRT/IMRT | 1.377(0.792–2.394) | 0.256 | ||
| Chemotherapy cycle | ||||
| 1 VS ≥2 | 0.977(0.580–1.645) | 0.929 | ||
| Number of LN examined | ||||
| <25 VS ≥25 | 0.829(0.504–1.364) | 0.460 | ||
| Lymph vessel invasion | ||||
| No VS Yes | 3.312(1.909–5.746) | <0.001 | 3.370(1.916–5.927) | <0.001 |
| Perineural invasion | ||||
| No VS Yes | 2.011(1.103–3.665) | 0.023 | 1.866(1.015–3.433) | 0.045 |
| Adjuvant chemotherapy | ||||
| No VS Yes | 0.945(0.574–1.557) | 0.825 | ||